Boundless Bio received FDA IND clearance for BBI‑940, an oral kinesin degrader, with a first‑in‑human KOMODO‑1 trial for metastatic breast cancer planned in H1. Separately, Immunomic Therapeutics secured an IND for ITI‑5000, enabling initiation of first‑in‑human studies. These green lights reflect continued early‑stage momentum in targeted protein degradation and vaccine/immune platform programs. IND approvals de‑risk near‑term clinical timelines and position both companies to generate human safety and pharmacology data that will determine next‑stage investment and partnering interest.